Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 9/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | HEXA | P06865 | 1/20 | 0.32 |
| ▸ | HEXB | P07686 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700330 | 1.00 | CDC25A (0.37) | CDC25ALMNAPKMRAB9ATRPA1 | |
| SCHEMBL3213143 | 0.83 | ITGB3 (0.48) | — | |
| SCHEMBL3225513 | 0.77 | ITGB3 (0.41) | — | |
| SCHEMBL6696591 | 0.74 | TRPA1 (0.46) | CDC25ARAB9ATRPA1NPC1MTOR | |
| SCHEMBL6696594 | 0.74 | TRPA1 (0.46) | CDC25ARAB9ATRPA1NPC1MTOR | |
| SCHEMBL3221444 | 0.71 | TRPA1 (0.40) | CDC25ARAB9ATRPA1NPC1MTOR | |
| SCHEMBL3221435 | 0.71 | TRPA1 (0.40) | CDC25ARAB9ATRPA1NPC1MTOR | |
| SCHEMBL3231078 | 0.70 | NR1H2 (0.51) | CDC25ARAB9ATRPA1NPC1MTOR | |
| SCHEMBL3231075 | 0.70 | NR1H2 (0.51) | CDC25ARAB9ATRPA1NPC1MTOR | |
| SCHEMBL3231552 | 0.70 | NR1H2 (0.51) | CDC25ARAB9ATRPA1NPC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | CDC25A 4025/4885LMNA 3929/4885PKM 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.